James Beretta
Pain Medicine · Pelham, ALNPI 1538148291
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $568 and has fallen 79.4% since, to $117 in 2025.
Across 147 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Scilex Pharmaceuticals Inc.$490
- Forte Bio-pharma LLC$323
- Collegium Pharmaceutical, Inc.$316
- IBSA Pharma Inc.$308
- Pfizer$186
- Sentynl Therapeutics, Inc.$120
- plus $649 from 22 others
What the payments were for
- Food & beverage$2,391100%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Scilex Pharmaceuticals Inc. | 34 | $490 |
| Forte Bio-pharma LLC | 4 | $323 |
| Collegium Pharmaceutical, Inc. | 20 | $316 |
| IBSA Pharma Inc. | 18 | $308 |
| Pfizer | 11 | $186 |
| Sentynl Therapeutics, Inc. | 15 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $111 |
| Merck | 6 | $83 |
| Daiichi Sankyo Inc. | 3 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Eisai Inc. | 3 | $36 |
| Assertio Therapeutics, Inc. | 2 | $34 |
| Amgen | 2 | $31 |
| GRT US Holding, Inc. | 2 | $26 |
| Redhill Biopharma Inc. | 1 | $26 |
| Almatica Pharma LLC | 2 | $24 |
| Zyla Life Sciences, Inc. | 2 | $24 |
| Stimwave Technologies Incorporated | 1 | $20 |
| Tonix Medicines, Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $17 |
| Averitas Pharma Inc. | 1 | $16 |
| AbbVie | 1 | $16 |
| Protega Pharmaceutials Inc | 1 | $15 |
| Boston Scientific | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Atland Pharmaceuticals, LLC | 1 | $14 |
| Virtus Pharmaceuticals LLC | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,391 in reported general payments places this provider in the 60th percentile of 77 pain medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 191 | $135,205 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 4,199 | $134,458 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 4,259 | $124,834 |
| OxycontinOxycodone Hcl | 195 | $100,624 |
| NucyntaTapentadol Hcl | 20 | $37,091 |
| Oxycodone Hcl | 1,606 | $35,711 |
| MovantikNaloxegol Oxalate | 40 | $32,026 |
| Nucynta ErTapentadol Hcl | 24 | $32,003 |
| Tizanidine Hcl | 924 | $27,415 |
| Gabapentin | 1,083 | $26,057 |
| Morphine Sulfate ErMorphine Sulfate | 637 | $24,208 |
| Pregabalin | 426 | $11,959 |
| Lidocaine | 57 | $11,533 |
| Methocarbamol | 442 | $11,479 |
| Fentanyl | 78 | $8,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta, Nucynta Er | $316 | $204,299235 claims |
| Redhill Biopharma Inc.Movantik | $26 | $32,02640 claims |
| MerckBelsomra | $83 | $7,67512 claims |
| Eisai Inc.Dayvigo | $36 | $5,87315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 77 pain medicine providers in Alabama.
Other pain medicine in Pelham
- Christopher PaulBirmingham$64K
- Michael CosgroveHuntsville$25K
- Ron PitkanenMountain Brk$16K
- Elliott PenningtonDaphne$15K
- James ThackerHuntsville$13K
- Grant StoneMobile$11K
- Hayden HundleyDothan$11K
- Hugh MaddoxAnniston$10K
- Jeremy BarlowVestavia Hills$9K
- Nitin ChhabraHoover$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.